	US 12,358,978 B2
	Anti-IL-27 antibodies and uses thereof
Jonathan Hill, Cambridge, MA (US); Scott Chappel, Cambridge, MA (US); Michael Gladstone, Cambridge, MA (US); Bianka Prinz, Lebanon, NH (US); Andrew Lake, Cambridge, MA (US); Christine Miller, Cambridge, MA (US); Kerry White, Cambridge, MA (US); Jing Hua, Cambridge, MA (US); Pamela M. Holland, Cambridge, MA (US); Matthew Rausch, Cambridge, MA (US); Devapregasan Moodley, Cambridge, MA (US); and Gege Tan, Cambridge, MA (US)
Assigned to SURFACE ONCOLOGY, LLC, Redwood City, CA (US)
Appl. No. 17/413,269
Filed by Surface Oncology, LLC, Redwood City, CA (US)
PCT Filed Sep. 25, 2019, PCT No. PCT/US2019/053036 § 371(c)(1), (2) Date Jun. 11, 2021, PCT Pub. No. WO2020/123011, PCT Pub. Date Jun. 18, 2020.
Claims priority of provisional application 62/779,341, filed on Dec. 13, 2018.
Prior Publication US 2022/0259299 A1, Aug. 18, 2022
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01)

CPC C07K 16/244 (2013.01) [A61P 35/00 (2018.01); A61P 37/04 (2018.01); C07K 16/24 (2013.01); C07K 16/2803 (2013.01); C07K 16/2827 (2013.01); C07K 16/2851 (2013.01); G01N 33/574 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/54 (2013.01)]

17 Claims

1. A monoclonal antibody that specifically binds human IL-27, or antigen binding portion thereof, wherein the antibody or antigen binding portion thereof comprises heavy and light chain CDRs selected from the group consisting of:

(i) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 706, 707 and 708, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 714, 715 and 716, respectively;

(ii) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 728, 729 and 730, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 736, 737 and 738, respectively;

(iii) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 750, 751 and 752, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 758, 759 and 760, respectively;

(iv) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 772, 773 and 774, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 780, 781 and 782, respectively;

(v) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 709, 710 and 711, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 717, 718 and 719, respectively;

(vi) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 731, 732 and 733, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 739, 740 and 741, respectively;

(vii) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 753, 754 and 755, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 761, 762 and 763, respectively; and

(viii) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 775, 776 and 777, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 783, 784 and 785, respectively.